Showing results (751-760 of 21,390) with videos related to

Sort By:
Pageof 2,139
The Journal of Experimental Medicine|January 1, 1993
Homozygous scid/scid;beige/beige mice have low levels of spontaneous or neonatal T cell-induced B cell generationD E Mosier, K L Stell, R J Gulizia, et al.
The Journal of Experimental Medicine|January 1, 1993
Major histocompatibility complex-specific prolongation of murine skin and cardiac allograft survival after in vivo depletion of V beta+ T cellsJ A Goss, R Pyo, M W Flye, et al.
The Journal of Experimental Medicine|January 1, 1993
Conventional B cells, not B-1 cells, are responsible for producing autoantibodies in lpr miceE A Reap, E S Sobel, P L Cohen, et al.
The Journal of Experimental Medicine|January 1, 1993
Site-specific alterations in the B oligomer that affect receptor-binding activities and mitogenicity of pertussis toxinY Lobet, C Feron, G Dequesne, et al.
The Journal of Experimental Medicine|January 1, 1993
The major histocompatibility complex-restricted response of recombinant inbred strains of mice to natural tick transmission of Borrelia burgdorferiW T Golde, T R Burkot, S Sviat, et al.
The Journal of Experimental Medicine|May 1, 1993
Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNAS Ikeyama, M Koyama, M Yamaoko, et al.
The Journal of Experimental Medicine|May 1, 1993
Glucocorticoid-mediated control of the activation and clonal deletion of peripheral T cells in vivoJ A Gonzalo, A González-García, C Martínez, et al.
The Journal of Experimental Medicine|May 1, 1993
Regulatory role of OX22high T cells in mercury-induced autoimmunity in the brown Norway ratP W Mathieson, S Thiru, D B Oliveira
The Journal of Experimental Medicine|May 1, 1993
Restricted kappa chain expression in early ontogeny: biased utilization of V kappa exons and preferential V kappa-J kappa recombinationsC A Medina, J M Teale
The Journal of Experimental Medicine|May 1, 1993
Selective immunosuppression by administration of major histocompatibility complex class II-binding peptides. II. Preventive inhibition of primary and secondary in vivo antibody responsesJ C Guéry, M Neagu, G Rodriguez-Tarduchy, et al.
Pageof 2,139